Shares of OncoSec Medical Inc (NASDAQ:ONCS) saw an uptick in trading volume on Thursday . 11,426,748 shares changed hands during trading, an increase of 6,740% from the previous session’s volume of 167,067 shares.The stock last traded at $2.21 and had previously closed at $1.64.
Several brokerages recently issued reports on ONCS. ValuEngine raised shares of OncoSec Medical from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Maxim Group set a $6.00 price target on shares of OncoSec Medical and gave the company a “buy” rating in a report on Wednesday, July 31st. Finally, Zacks Investment Research downgraded shares of OncoSec Medical from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $19.75.
The firm’s fifty day moving average is $1.98 and its 200-day moving average is $1.77.
In related news, Director Alpha Holdings, Inc. acquired 90,000 shares of the stock in a transaction on Tuesday, July 16th. The stock was purchased at an average price of $2.30 per share, for a total transaction of $207,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 5.40% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of ONCS. JPMorgan Chase & Co. acquired a new stake in OncoSec Medical in the 2nd quarter valued at about $46,000. Private Advisor Group LLC acquired a new stake in OncoSec Medical in the 2nd quarter valued at about $27,000. Worth Venture Partners LLC acquired a new stake in OncoSec Medical in the 2nd quarter valued at about $99,000. Finally, Citadel Advisors LLC acquired a new stake in OncoSec Medical in the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 5.83% of the company’s stock.
About OncoSec Medical (NASDAQ:ONCS)
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
Recommended Story: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.